Human Rabies Vaccine Vero Cell For Post Exposure Prevention

AIM Honor (Ningbo) Biopharmaceutical Co., Ltd., a trusted China supplier and one of the world's second-largest rabies vaccine manufacturers, offers Human Rabies Vaccine Vero Cell For Post Exposure Prevention as a vital defense against rabies virus infection following potential exposure. This inactivated vaccine, produced using advanced Vero cell technology with domestically developed high-efficacy aG virus strains, is specifically designed for post-exposure prophylaxis in individuals bitten, scratched, or otherwise exposed to potentially rabid animals. With no preservatives or antibiotics added during production, the vaccine delivers an exceptional safety profile while achieving 100% antibody seroconversion within 14 days of the standard five-dose regimen, providing rapid, reliable immune protection when time is critical. Suitable for all age groups and both genders, it represents a preferred choice for rabies control programs worldwide.

Post-Exposure Protection

Rabies is a viral disease that causes acute encephalitis in mammals, with a fatality rate approaching 100% once clinical symptoms appear. Post-exposure prophylaxis (PEP) is the only effective way to prevent rabies from developing after a person has been exposed to the virus. Timely and proper administration of rabies vaccine, combined with appropriate wound care, can effectively prevent the onset of this deadly disease.

Our Human Rabies Vaccine Vero Cell For Post Exposure Prevention is specifically formulated for post-exposure use, providing rapid induction of neutralizing antibodies that can stop the virus from reaching the central nervous system. The high-titer antigen formulation ensures a robust immune response, with complete antibody seroconversion achieved within 14 days of starting the standard vaccination schedule. This rapid seroconversion is critical in post-exposure scenarios, where the race between vaccine-induced immunity and viral progression to the brain determines the outcome.

The vaccine is suitable for post-exposure prophylaxis in all populations, regardless of age or gender. Whether the exposure comes from a dog bite, cat scratch, or contact with any other potentially rabid animal, immediate wound cleaning followed by prompt vaccination according to the recommended schedule provides the best chance of preventing this fatal disease. The World Health Organization recognizes post-exposure vaccination as an essential component of any comprehensive rabies control strategy.

Mechanism of Action

Understanding how the vaccine works helps explain why timely post-exposure vaccination is so effective at preventing rabies. The vaccine operates through a well-established immunological mechanism that trains the body's immune system to recognize and neutralize the rabies virus.

The vaccine contains inactivated rabies fixed virus (aGV strain) that has been grown in Vero cells, harvested, inactivated, concentrated, and purified. When injected into the body, these inactivated viral particles act as antigens—they cannot cause disease but are recognized by the immune system as foreign invaders. The immune system responds by producing specific antibodies against the rabies virus, as well as memory cells that provide long-term protection.

These neutralizing antibodies work by binding to the rabies virus particles, preventing them from entering nerve cells and traveling toward the central nervous system. In post-exposure scenarios, the vaccine-induced antibodies intercept the virus at the site of exposure and during its journey along peripheral nerves, effectively blocking its path to the brain before it can cause irreversible damage.

The Vero cell production platform contributes to the vaccine's consistent immunogenicity and safety profile. Vero cells provide a stable, well-characterized substrate for virus cultivation, enabling the production of high-titer virus suspensions that can be concentrated and purified to achieve the required antigen potency. The result is the Human Rabies Vaccine Vero Cell For Post Exposure Prevention with reliable immunogenicity batch after batch.

Product Specifications

The following table summarizes the key specifications of our human rabies vaccine for post-exposure prevention:

The freeze-dried presentation offers several important advantages for post-exposure use. The lyophilized form maintains antigen stability during storage and transport, ensuring that the vaccine retains its full potency throughout its 36-month shelf life when stored at the recommended temperature of +2°C to +8°C. This stability is particularly valuable for regions where maintaining a reliable cold chain can be challenging.

Each dose is supplied with its own vial of sterile water for injection diluent, allowing for reconstitution immediately before administration. After reconstitution, the vaccine appears as a clear liquid, ready for intramuscular injection. The 1.0 ml dose volume is designed for convenient administration in the deltoid muscle of the upper arm (or the anterolateral thigh muscle for young children).

The vaccine contains no preservatives and no antibiotics, which reduces the risk of allergic reactions and contributes to its excellent safety profile. The excipients—human albumin, gelatin, sucrose, and PBS—serve as stabilizers to protect the antigen during the freeze-drying process and throughout storage. These carefully selected components ensure that the Human Rabies Vaccine Vero Cell For Post Exposure Prevention maintains its full potency from production through administration.

Vaccination Protocol

Proper adherence to the recommended vaccination schedule is essential for ensuring optimal protection following rabies exposure. The following guidelines outline the standard post-exposure vaccination protocol:

1. Wound Care First: Immediately after any potential rabies exposure, the wound should be thoroughly cleaned with soap and water or clean water, followed by application of iodine tincture or ethanol. Proper wound care is the first critical step in post-exposure prophylaxis and should never be delayed while waiting for vaccine availability.

2. Standard Five-Dose Schedule: The standard post-exposure immunization regimen consists of five doses administered on days 0 (the day of first vaccination), 3, 7, 14, and 28. Each dose is given by intramuscular injection. This schedule applies to all age groups, including children, who receive the same dose volume as adults.

3. Doubled First Dose Conditions: In certain circumstances, it is recommended to double the first dose of vaccine. These conditions include individuals who received rabies immunoglobulin or antiserum one day or earlier before vaccination, those with congenital or acquired immunodeficiency, patients receiving immunosuppressive therapy including antimalarial drugs, elderly individuals, and those who begin vaccination 48 hours or more after exposure.

4. Wound Category Considerations: Post-exposure treatment varies based on wound severity classification. Category II exposures (bites or scratches without bleeding) require vaccination alone following the standard schedule. Category III exposures (bites with bleeding, scratches with bleeding, or mucous membrane contamination by animal saliva) require both rabies vaccine and rabies immunoglobulin or antiserum, with infiltration of the immunoglobulin around the wound whenever anatomically feasible.

5. Re-exposure Guidelines: For individuals who have previously completed a full rabies vaccination course, re-exposure recommendations depend on the timing of the previous vaccination. Those vaccinated within the past year typically need only two booster doses (days 0 and 3). Those vaccinated more than one year ago should complete the full five-dose schedule. Specific recommendations vary based on the exact timing and nature of previous immunization.

The vaccine is administered by intramuscular injection into the deltoid muscle of the upper arm for adults and older children. For younger children, the anterolateral aspect of the thigh is the recommended injection site. The vaccine should never be administered in the gluteal region, as absorption may be unreliable from this site. Proper administration technique is essential to ensure the Human Rabies Vaccine Vero Cell For Post Exposure Prevention delivers its full immunogenic potential.

Safety & Tolerability

Safety is a paramount consideration for any vaccine, and our Vero cell rabies vaccine has been carefully evaluated through extensive clinical use and post-marketing surveillance. The vaccine's excellent safety profile makes it suitable for post-exposure use across all populations.

Common adverse reactions are generally mild and transient. Local reactions may include redness, swelling, pain, or itching at the injection site within 24 hours after vaccination. These local symptoms typically resolve spontaneously without requiring specific treatment. Systemic reactions may include low-grade fever, malaise, headache, dizziness, joint pain, muscle pain, vomiting, and abdominal pain. Like local reactions, these systemic symptoms are usually mild and resolve on their own without medical intervention.

Rare adverse reactions include transient moderate to severe fever, which may require physical cooling or symptomatic treatment to prevent febrile seizures, particularly in young children. Such reactions are uncommon and can be managed effectively with appropriate medical attention.

Extremely rare adverse reactions, while very uncommon, may include allergic rash (urticaria), anaphylactic shock, allergic purpura, angioneurotic edema, and nervous system reactions. These serious reactions require immediate medical attention. It is important to note that because rabies is a universally fatal disease, there are no contraindications for post-exposure immunization—the benefit of preventing rabies far outweighs any potential risk of adverse reaction.

The absence of preservatives and antibiotics in the vaccine formulation contributes to its favorable safety profile by eliminating common sources of allergic reactions. The advanced purification technology used during manufacturing—including ultrafiltration and chromatography systems—effectively removes foreign proteins, DNA, and other impurities, further reducing the risk of adverse reactions and ensuring high antigen purity.

Healthcare providers administering the vaccine should be prepared to manage potential allergic reactions, and emergency medications such as adrenaline should be readily available. Vaccination should always be performed by trained healthcare professionals in settings where emergency medical support is accessible.

Quality Manufacturing

The reliability and consistency of any vaccine depend on the quality of its manufacturing process. AIM Honor produces rabies vaccine in a professional, modern GMP-certified workshop, with rigorous quality control at every stage of production.

The production process begins with virus cultivation using Vero cells as the substrate. The aG virus strain—a domestically developed, highly effective strain—is used to infect the Vero cell cultures, which then produce high-titer virus suspensions. This cultivation step is performed in a closed sterile operation system within a B+A grade clean environment, with the operations team wearing fully enclosed protective equipment to prevent any external contamination. High-precision culture equipment carefully controls parameters such as temperature and pH to ensure strain activity and cell proliferation stability.

Following cultivation and harvest, the virus suspension undergoes inactivation, concentration, and purification. Advanced purification technology employs a 20m² ultrafiltration system and 600mm chromatography system for multi-step purification, effectively removing foreign proteins, DNA, and other impurities. This results in high antigen purity that meets global standards. The company implements internal control standards stricter than national pharmacopoeia requirements, including endotoxin levels of ≤10 EU per dose, sterility assurance, and strict pH value control, ensuring product quality stability and consistency batch after batch.

The final formulation stage uses standardized freeze-drying technology with a 40m² freeze-drying system. This process reduces moisture content in the product, extending shelf life and maintaining antigen activity. The entire preparation process is controlled in a B+A grade clean environment, ensuring the highest levels of product safety. The freeze-dried presentation results in a white, crisp cake that reconstitutes into a clear liquid when mixed with the provided diluent.

AIM Honor (Ningbo) Biopharmaceutical Co., Ltd. has been producing rabies vaccine (Vero cell) since 2001, when it obtained the new drug certificate. The company received GMP certification and drug production approval in 2002, and obtained registration approval for the freeze-dried formulation in September 2007. With an annual production capacity of approximately 22 million doses, AIM Honor ranks as the second-largest manufacturer of human rabies vaccine in China and globally, demonstrating both production scale and manufacturing expertise.

As a subsidiary of AIM Vaccine Co., Ltd.—a Hong Kong-listed company (Stock Code: 06660.HK) and one of China's leading vaccine companies—AIM Honor benefits from the group's full-industry-chain advantages spanning R&D, manufacturing, and commercialization. The group operates four fully controlled licensed vaccine manufacturing companies, three vaccine research institutes, and four R&D centers, with seven R&D teams driving product pipeline advancement.

FAQ

Q: How soon after exposure should I start vaccination?

A: Vaccination should begin as soon as possible after potential rabies exposure. The sooner the vaccine is administered after exposure, the better the chance of preventing the virus from reaching the central nervous system. However, even if some time has passed since exposure, vaccination should still be started immediately—it is never too late to begin post-exposure prophylaxis, as long as the person has not yet developed symptoms of rabies.

Q: Is the vaccine safe for children and elderly people?

A: Yes, the vaccine is suitable for all age groups, including children and elderly individuals. The dose volume is the same for all ages. Because rabies is fatal once symptoms appear, there are no contraindications for post-exposure vaccination regardless of age or health status. For elderly individuals or those with certain conditions, a doubled first dose may be recommended to ensure an adequate immune response.

Q: What should I do if I miss a scheduled dose?

A: If a dose is delayed, the vaccination series should be continued with the remaining doses according to the original schedule spacing—do not restart the series. For example, if the day 3 dose is given late, the day 7 dose should still be given 4 days after the day 3 dose, maintaining the interval between doses. It is best to stay on schedule as closely as possible, but partial delays do not require restarting the entire course.

Q: Can the vaccine be given during pregnancy?

A: Because rabies is almost universally fatal once symptoms develop, post-exposure vaccination is recommended for pregnant women who have been exposed to rabies. The benefit of preventing this deadly disease far outweighs any theoretical risks. The vaccine has been used extensively in pregnant women with no evidence of harm to the fetus. As with any medical decision during pregnancy, consultation with a healthcare provider is advisable.

Q: How is the vaccine stored and transported?

A: The vaccine must be stored and transported between +2°C and +8°C, protected from light. It should never be frozen. Maintaining the cold chain is essential for preserving vaccine potency. The 36-month shelf life applies when the vaccine is stored under these recommended conditions. For international shipments, we use cold chain logistics to ensure the product maintains proper temperature throughout transit.

Q: What is the delivery time for bulk orders?

A: Standard delivery time is approximately 30 working days after receiving payment, though this may vary based on order specifics and quantity. We support bulk purchasing and cross-border supply, with the production capacity to handle large orders reliably. For urgent requirements, please contact our sales team to discuss possible expedited options.

Q: Do you provide samples for evaluation?

A: Yes, we can provide a limited number of sample vials for evaluation purposes. Sample availability and conditions may vary by region. Please contact our sales team to discuss your specific sample requirements and to confirm availability in your country.

Q: What certifications does your manufacturing facility hold?

A: Our manufacturing facility operates under GMP (Good Manufacturing Practices) certification and holds the necessary drug production licenses. AIM Honor obtained GMP certification in 2002 and has maintained continuous compliance since then. The company is actively working toward PIC/S member country inspection as part of its ongoing quality improvement efforts. Our quality control standards are stricter than national pharmacopoeia requirements for multiple key parameters.